Microcap Ledger OmniAb, Inc. $OABI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Services-Commercial Physical & Biological Research
- Headquarters
- Emeryville, CA
- Fiscal year end
- December 31
- Shares outstanding
- 145,390,398 [10-Q 2026-08-06]
What the company doesAI summary of filing
OmniAb licenses antibody discovery technology to pharmaceutical, biotechnology, and academic partners. The company develops and operates transgenic animal platforms (including OmniRat, OmniChicken, OmniMouse, and OmniTaur) engineered to produce human antibodies, paired with high-throughput screening technologies and artificial intelligence tools. OmniAb generates revenue through upfront access fees, research services, milestone payments, and royalties on commercial sales of partner-developed products. As of December 31, 2025, the company had 107 active partners with 407 active programs, including 27 programs in clinical development, 2 under regulatory review, and 3 approved products commercialized by partners. [10-K 2026-03-04]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $27.84M | −$13.57M | −$2.23M | $24.34M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $18.67M | −$64.78M | −$36.45M | $25.52M | [10-K 2026-03-04] |
| FY ended Dec 2024 | $26.39M | −$62.03M | −$39.66M | $27.60M | [10-K 2026-03-04] |
- Quarterly cash burn
- −$1.12M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 121,012,583 | [10-Q 2024-11-12] |
| 2025-03-11 | 122,134,941 | [10-K 2025-03-18] |
| 2025-05-01 | 122,335,336 | [10-Q 2025-05-08] |
| 2025-07-30 | 122,701,294 | [10-Q 2025-08-06] |
| 2025-10-28 | 143,955,400 | [10-Q 2025-11-04] |
| 2026-02-25 | 144,782,647 | [10-K 2026-03-04] |
| 2026-04-30 | 144,972,579 | [10-Q 2026-05-07] |
| 2026-07-30 | 145,390,398 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-09-12; declared effective 2025-09-19 [S-3 2025-09-12]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-17 | Bertozzi Carolyn R | exercise | 20,000 | — | [4 2026-06-18] |
| 2026-06-17 | Cochran Jennifer R. | exercise | 20,000 | — | [4 2026-06-18] |
| 2026-06-17 | Crouse Steven C. | exercise | 20,000 | — | [4 2026-06-18] |
| 2026-06-17 | Gotwals Philip J | exercise | 20,000 | — | [4 2026-06-18] |
| 2026-06-17 | Higgins John L | exercise | 20,000 | — | [4 2026-06-18] |
| 2026-06-17 | Love Steven | exercise | 20,000 | — | [4 2026-06-18] |
| 2026-04-21 | Gotwals Philip J | exercise | 13,333 | — | [4 2026-04-21] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-13 | 8-K | Director or officer change |
| 2026-06-18 | 8-K | Shareholder vote results |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-29 | DEF 14A | Proxy statement |
| 2026-03-04 | 10-K | Annual report |
| 2026-03-04 | 8-K | Results of operations |
| 2026-02-10 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-01-30 | 8-K | Charter, bylaws or fiscal year change |
Alerts for $OABI
Email me when OmniAb, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.